Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors

Journal of Molecular Modeling

Volumn 18, Issue 3, 2012, Pages 1207-1218

  Wu, Xiaoyun ^a   Wu, Shuguang ^a   Chen, Wen Hua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

4 (1H Indazol 4 yl)phenylamino derivatives; Aminopyrazolopyridine ureas; CoMFA; CoMSIA; KDR inhibitor; Surflex dock

Indexed keywords

4 (1H INDAZOL 4 YL)PHENYLAMINO DERIVATIVE; AMINOPYRAZOLOPYRIDINE UREA DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING SITE; CHEMICAL INTERACTION; DRUG BINDING; DRUG POTENCY; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR DOCKING; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIMULATION; STATIC ELECTRICITY;

AMINES; COMPUTER SIMULATION; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; UREA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

RUMEX;

EID: 84861331693     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-011-1146-9     Document Type: Article

References (23)

1. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674 (Pubitemid 27193480)
2. Ribatti D, Vacca A, Nico B, Roncali L, Dammacco F (2001) Postnatal vasculogenesis. Mech Dev 100:157-163 (Pubitemid 32109326)
3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
4. Hanahan D, Folkmann J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364 (Pubitemid 26272076)
5. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336 (Pubitemid 121001258)
6. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027 (Pubitemid 46202320)
7. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611 (Pubitemid 39099316)
8. Baka S, Clamp AR, Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10:867-876 (Pubitemid 44816749)
9. Sepp-Lorenzino L, Thomas KA (2002) Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Expert Opin Invest Drugs 11:1447-1465 (Pubitemid 35174940)
10. Klebl BM, Müller G (2005) Second-generation kinase inhibitors. Expert Opin Ther Targets 9:975-993 (Pubitemid 41488835)
11. Supuran CT, Scozzafava A (2004) Protein tyrosine kinase inhibitors as anticancer agents. Expert Opin Ther Pat 14:35-53 (Pubitemid 38072656)
12. Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 19:2003-2012 (Pubitemid 47354167)
13. Sakamoto KM (2004) SU-11248 (SUGEN). Curr Opin Invest Drugs 5:1329-1339
14. Ahman T, Eisen T (2004) Kinase inhibition with BAY43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388s-6392s (Pubitemid 39302607)
15. Dai YJ, Hartandi K, Ji ZQ, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'- (2- fluoro-5- methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584-1597 (Pubitemid 46564379)
16. Dai YJ, Hartandi K, Soni NB, Pease LJ, Reuter DR, Olson AM, Osterling DJ, Doktor SZ, Albert DH, Bouska JJ, Glaser KB, Marcotte PA, Stewart KD, Davidsen SK, Michaelides MR (2008) Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 18:386-390
17. Cramer RD 3rd, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967
18. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146 (Pubitemid 24379702)
19. SYBYL 7.3 is available from Tripos Associates Inc, 1699 S Hanley Rd, St Louis, MO 631444, USA
20. Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499-511 (Pubitemid 36182752)
21. Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21:281-306 (Pubitemid 46630055)
22. Pan J, Liu GY, Cheng J, Chen XJ, Ju XL (2010) CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors. Eur J Med Chem 45:967-972
23. Sun JY, Cai SX, Yan N, Mei H (2010) Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using threedimensional holographic vector of atomic interaction field analysis. Eur J Med Chem 45:1008-1014